Profile data is unavailable for this security.
About the company
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
- Revenue in USD (TTM)13.38m
- Net income in USD-241.11m
- Incorporated2010
- Employees78.00
- LocationVerastem Inc117 Kendrick Street, Suite 500NEEDHAM 02494United StatesUSA
- Phone+1 (781) 292-4200
- Fax+1 (302) 655-5049
- Websitehttps://www.verastem.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upstream Bio Inc | 2.80m | -122.77m | 416.10m | 52.00 | -- | 1.10 | -- | 148.66 | -2.30 | -2.30 | 0.0527 | 7.01 | 0.009 | -- | 4.34 | 53,826.92 | -39.18 | -- | -40.67 | -- | -- | -- | -4,366.77 | -- | -- | -- | 0.00 | -- | -0.4202 | -- | -99.70 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -39.95m | 419.80m | 34.00 | -- | 3.32 | -- | -- | -0.4649 | -0.4649 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -31.08 | -33.08 | -33.63 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
| Absci Corp | 2.82m | -114.60m | 421.04m | 156.00 | -- | 1.99 | -- | 149.57 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
| Keros Therapeutics Inc | 246.72m | 64.45m | 423.78m | 82.00 | 9.01 | 0.8033 | 6.43 | 1.72 | 1.54 | 1.54 | 6.07 | 17.32 | 0.3732 | -- | 127.17 | 1,459,870.00 | 9.75 | -36.26 | 10.16 | -38.17 | -- | -- | 26.12 | -2,307.89 | -- | -- | 0.00 | -- | 2,250.99 | -18.71 | -22.46 | -- | 48.10 | -- |
| Lenz Therapeutics Inc | 17.50m | -58.88m | 428.05m | 42.00 | -- | -- | -- | 24.46 | -2.11 | -2.11 | 0.6268 | -- | -- | -- | -- | 416,666.70 | -- | -39.77 | -- | -42.56 | -- | -- | -336.47 | -- | -- | -- | -- | -- | -- | -- | 60.07 | -- | -- | -- |
| Tectonic Therapeutic Inc | 0.00 | -74.15m | 431.86m | 60.00 | -- | 1.71 | -- | -- | -4.04 | -4.04 | 0.00 | 13.41 | 0.00 | -- | -- | 0.00 | -35.83 | -- | -37.77 | -- | -- | -- | -- | -- | -- | -- | 0.0015 | -- | -- | -- | -27.89 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -23.56m | 436.00m | 18.00 | -- | 33.42 | -- | -- | -0.7742 | -0.7742 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -104.21 | -108.46 | -169.47 | -146.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.11 | -- | 176.33 | -- |
| Entrada Therapeutics Inc | 25.42m | -143.75m | 447.16m | 152.00 | -- | 1.46 | -- | 17.59 | -3.47 | -3.47 | 0.6145 | 8.00 | 0.0563 | -- | 10.47 | 167,243.40 | -31.81 | -13.07 | -34.24 | -15.14 | -- | -- | -565.48 | -63.14 | -- | -- | 0.00 | -- | -87.94 | -- | -319.04 | -- | -14.85 | -- |
| PepGen Inc | 0.00 | -93.56m | 448.93m | 81.00 | -- | 2.75 | -- | -- | -2.84 | -2.84 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -51.93 | -45.06 | -56.56 | -49.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | 76.52 | -- |
| Verastem Inc | 13.38m | -241.11m | 449.04m | 78.00 | -- | -- | -- | 33.56 | -4.02 | -4.02 | 0.2209 | -0.2326 | 0.0882 | -- | 3.76 | 171,525.60 | -159.03 | -68.26 | -233.92 | -83.33 | 85.14 | -- | -1,802.12 | -417.53 | 2.55 | -- | 1.21 | -- | -- | -10.54 | -49.53 | -- | 31.95 | -- |
| Lineage Cell Therapeutics Inc | 10.82m | -67.66m | 449.14m | 70.00 | -- | 20.38 | -- | 41.53 | -0.2955 | -0.2955 | 0.0469 | 0.0957 | 0.1162 | -- | 40.66 | 154,514.30 | -72.50 | -20.81 | -81.52 | -24.54 | 97.84 | 90.99 | -624.16 | -331.61 | -- | -- | 0.004 | -- | 6.19 | 22.00 | 13.39 | -- | 5.13 | -- |
| Regenxbio Inc | 161.32m | -177.92m | 467.76m | 353.00 | -- | 2.90 | -- | 2.90 | -3.46 | -3.46 | 3.14 | 3.19 | 0.3089 | -- | 6.59 | 456,991.50 | -34.07 | -20.33 | -43.55 | -23.79 | 87.18 | 76.64 | -110.29 | -82.78 | -- | -6.74 | 0.5427 | -- | -7.66 | 18.79 | 13.81 | -- | -26.96 | -- |
| Altimmune Inc | 20.00k | -83.92m | 469.39m | 59.00 | -- | 2.14 | -- | 23,469.39 | -1.07 | -1.07 | 0.0003 | 1.94 | 0.0001 | -- | 0.0314 | 338.98 | -45.82 | -42.36 | -48.64 | -45.46 | -- | -- | -419,575.00 | -3,193.88 | -- | -- | 0.0722 | -- | -95.31 | -67.83 | -7.48 | -- | -- | -- |
| Assembly Biosciences Inc | 37.19m | -38.55m | 469.45m | 73.00 | -- | 2.57 | -- | 12.62 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| 4D Molecular Therapeutics Inc | 120.00k | -209.18m | 475.90m | 227.00 | -- | 1.18 | -- | 3,965.86 | -3.74 | -3.74 | 0.0022 | 7.89 | 0.0002 | -- | -- | 528.63 | -40.70 | -32.02 | -43.51 | -33.96 | -- | -- | -174,314.20 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 481.54m | 123.00 | -- | 38.39 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Verastem Inc's reporting currency: US Dollar USD
63.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Dec 2025 | 6.58m | 10.69% |
| Deep Track Capital LPas of 31 Dec 2025 | 5.74m | 9.33% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.17m | 6.78% |
| Polar Capital LLPas of 31 Dec 2025 | 3.93m | 6.38% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.68m | 5.99% |
| Armistice Capital LLCas of 31 Dec 2025 | 3.54m | 5.75% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.22m | 5.23% |
| Balyasny Asset Management LPas of 31 Dec 2025 | 3.20m | 5.19% |
| Stonepine Capital Management LLCas of 31 Dec 2025 | 2.73m | 4.44% |
| Farallon Capital Management LLCas of 31 Dec 2025 | 2.00m | 3.25% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
